Biomarkers /
NT5E
Overview
NT5E is altered in 1.20% of all cancers with breast invasive ductal carcinoma, breast invasive lobular carcinoma, mixed lobular and ductal breast carcinoma, and mucinous breast carcinoma having the greatest prevalence of alterations [3].
The most common alterations in NT5E are NT5E Amplification (0.66%), NT5E Mutation (0.37%), NT5E Loss (0.12%), NT5E A5T (0.08%), and NT5E A567T (0.04%) [3].
Clinical Trials
Significance of NT5E in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.